OTLC — Oncotelic Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Mateon Therapeutics terminates FOCUS study in ovarian cancer
Brief: Mateon qtrly loss per share $0.15
Brief: Mateon announces presentation of oxi4503 AML study data
Brief: Mateon Q3 net loss $3.2 million
Brief: Mateon says board now consists of six directors
Brief: Mateon announces issuance of US patent for Cathepsin
Brief: Mateon says William D. Schwieterman appointed chairman of the board
Brief: Mateon Therapeutics Q2 loss per share $0.14
Brief: Mateon announces initiation of focus study in platinum-resistant ovarian cancer
Brief: Oxigene announces name change to Mateon Therapeutics
Brief: Oxigene receives U.S. orphan drug designation for CA4P to treat glioma
Brief: Oxigene says Phase 2 study of CA4P met primary endpoint of improvement
Brief: Oxigene qtrly loss per share $0.13
Brief: Oxigene receives fast track status from U.S. FDA for CA4P
Brief: Oxigene says receives European orphan drug designation for CA4P
Brief: Oxigene says U.S. FDA approved protocol for focus, phase 2/3 study of ca4p for the treatment of platinum-resistant ovarian cancer
Brief: Oxigene gets U.S. orphan drug designation for neuroendocrine tumors drug
Brief: Oxigene reports Q3 2015 financial results
Brief: Oxigene announces positive initial data from phase 1b study of CA4P in combination with pazopanib